Held by 5 specialist biotech funds
High Convergence# Signal Note: Avoro Capital Initiates $37.7M Position in APGE Avoro's entry suggests conviction in Apogee's clinical-stage pipeline, likely driven by upcoming catalysts in its lead program (monoclonal antibody targeting TL1A for inflammatory bowel disease) where Phase 2b readout is expected in 2024-2025.
AI analyst context — unlock full analysis
# Signal Note: Perceptive Initiates $176M Position in Apogee Therapeutics Edelman's new 2.3M share position signals conviction in Apogee's clinical pipeline, likely anchored on APG-157 (a selective PI3K-delta inhibitor for atopic dermatitis) which has demonstrated Phase 2b efficacy and is advancing toward Phase 3. The timing suggests positioning ahead of near-term data readouts or trial initiations that could de-risk the lead program and establish proof-of-concept in a large indication.
+ 3 more positions with dollar amounts and AI context
Unlock All — 7-Day Free Trial